-
CMAJ: Study on the incidence of cancer in children in Canada during the COVID-19 pandemic (No. 26)
Time of Update: 2021-12-24
During the first 9 months of the COVID-19 pandemic, we did not observe a statistically significant change in the incidence of childhood cancer or the proportion of children who participated in clinical trials, showed metastatic disease or died prematurely, the report shows , In Canada, the chances of childhood cancer patients' access to medical care have not been significantly reduced .
-
Clinical Guidelines for Radiotherapy of Non-Small Cell Lung Cancer in China (2020 Edition)
Time of Update: 2021-12-24
Source: Chinese Journal of Radiation OncologySource: Chinese Journal of Radiation Oncology Source: Chinese Journal of Radiation OncologyCite this article: Chinese Medical Association Radiation Oncology Therapeutics Branch, Chinese Medical Doctor Association Radiation Oncology Therapeutics Branch, Chinese Anti-Cancer Association Radiotherapy Professional Committee, Chinese Clinical Oncology Society Tumor Radiotherapy Expert Committee.
-
J Clin Oncol: Efficacy and safety of CHOP regimen plus romidepsin in the treatment of relapsed/refractory peripheral T-cell lymphoma
Time of Update: 2021-12-24
In summary, on the basis of the CHOP regimen, the addition of romidepsin did not improve the progression-free survival, remission rate and overall survival of patients with previously untreated peripheral T-cell lymphoma, and it also increased ≥3 grades The incidence of adverse events requiring urgent treatment .
-
Clin Cancer Res: Results of the first clinical trial of HER2 bispecific antibody KN026 monotherapy for HER2+ metastatic breast cancer
Time of Update: 2021-12-24
The HER2 bispecific antibody KN026 is well tolerated in patients with metastatic breast cancer, and its therapeutic effect is comparable to the dual treatment of trastuzumab and pertuzumab.
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study .
-
Nature Cancer: Zhang Huafeng/Gao Ping collaborated to reveal a new mechanism for ENO1 to promote liver cancer by inhibiting iron death
Time of Update: 2021-12-24
Recently, the University of Science and Technology of China Zhang Huafeng Task Force and the Task Force Gaoping (now South China University of Technology) in Nature Cancer journal published online entitled: ENOl suppresses the Cell Cancer ferroptosis by degrading at The Iron Regulatory Protein 1 mRNA of research papers .
-
Oral Dis: topical vitamin D gel can reduce the development of oral mucositis and relieve pain
Time of Update: 2021-12-24
Vitamin D preventionThe study finally included 45 patients with head and neck cancer and conducted a three-arm randomized controlled clinical trial: the first group was the conventional treatment group; the second group was the topical oral vitamin D gel; the third group was the topical oral vitamin D gel combination Routine treatment .
-
NICE recommends pembrolizumab as an adjuvant therapy for stage 3 melanoma
Time of Update: 2021-12-24
5-year survival rate without distant metastasis in the pembrolizumab group was higher than that in the placebo group (p<0.
5-year survival rate without distant metastasis in the pembrolizumab group was higher than that in the placebo group (p<0.
-
NICE recommends venetoclax combined with azacitidine for patients with aggressive blood cancer
Time of Update: 2021-12-24
Compared with azacitidine therapy alone, NICE's decision to approve the combination therapy provides patients with a treatment option that can significantly improve overall survival, rapid and durable remission, and independence from blood transfusion .
-
J Clin Invest: Fractional laser resurfacing treatment can effectively reduce the risk of non-melanoma skin cancer in aging skin
Time of Update: 2021-12-24
Recently, researchers from the United States have explored the mechanism by which IGF-1 signaling affects photocarcinogenesis during chronic UVB exposure to determine whether Fractional Laser Resurfacing (FLR) of elderly skin that raises dermal IGF-1 levels can prevent actinization.
-
Nature Communications: Shanghai Science and Technology Okura Yong team reveals a new mechanism for cancer to escape immunotherapy in tumor evolution
Time of Update: 2021-12-24
However, most patients cannot respond well to the therapy and maintain a long-lasting effect, mainly because tumors have accumulated a large number of gene mutations during the evolution process, and have acquired genetic heterogeneity, which can be used in immunotherapy.
-
Eur Urol: Patient preference of the first-line chemotherapy drugs cabazitaxel and docetaxel in metastatic castration-resistant prostate cancer
Time of Update: 2021-12-24
They have similar efficacy in the first-line mCRPC treatment, but the safety status is differentRecently, researchers from France published an article in the "Eur Urol" magazine, evaluating the preference of docetaxel and cabazitaxel.
-
Clin Cancer Res: Pembrolizumab combined with Acalabrutinib in the treatment of recurrent/metastatic head and neck squamous cell carcinoma
Time of Update: 2021-12-24
This study is a multi-center, open-label, randomized phase 2 clinical trial to evaluate the effectiveness and safety of anti-PD-1 monoclonal antibody pembrolizumab combined with BTK inhibitor Acalabrutinib in the treatment of relapsed or metastatic HNSCC Sex .
-
Clin Cancer Res: Lacnotuzumab combined with gemcitabine-carboplatin in the treatment of advanced triple-negative breast cancer
Time of Update: 2021-12-24
In summary, Lacnotuzumab+gemcitabine+carboplatin showed comparable anti-tumor activity to gemcitabine+carboplatin alone in advanced TNBC, but the tolerance was slightly poor .
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
-
SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer
Time of Update: 2021-12-24
Recently, Bristol-Myers Squibb (BMS) announced that the Scottish Pharmaceutical Union (SMC) has accepted Nivolumab in combination with ipilmumab as a late mismatch repair defect (dMMR) or high microsatellite instability (MSIH)Treatment options for adults with colorectal cancer , these patients have failed previous fluoropyrimidine-based chemotherapy, and the therapy is used by the NHS in Scotland .
-
NEJM: Post-cytoreductive chemotherapy can significantly improve the prognosis of patients with recurrent ovarian cancer
Time of Update: 2021-12-24
The patients received platinum-free chemotherapy for the first recurrence after at least 6 months, and randomly received two cytoreductive surgery (operation group) or control (platinum chemotherapy alone), followed by platinum chemotherapy .
-
Front Oncol: The effect of TMB status on the efficacy of anti-HER2 therapy in HER2-positive advanced gastric cancer (AGC)
Time of Update: 2021-12-24
The status of TMB may be a new biomarker predicting the efficacy of trastuzumab combined with chemotherapy in the treatment of HER2-positive AGC patients .
-
Thorac Cancer: Real-world data on advanced or metastatic NSCLC patients with rare mutations
Time of Update: 2021-12-24
Lung cancer NSCLCThe study retrospectively included patients with advanced or metastatic non-squamous NSCLC aged> 20 years from 9 tertiary hospitals in South Korea between January 2015 and September 2020, who were confirmed to have rare mutations (BRAF, ROS1, MET, RET).
-
Cochrane Database Syst Rev: Application of Blue Light vs. White Light TURBT in Transurethral Resection of Non-muscle Invasive Bladder Cancer
Time of Update: 2021-12-24
Compared with white light TURBT, the use of blue light-enhanced TURBT for the treatment of non-muscle invasive bladder cancer may reduce the risk of disease recurrence and progression, and the reduction effect varies depending on the baseline risk.
-
Professor Chen Xiaobing, an expert in oncology science, "Facing Cancer: Don't Panic or Follow Blindly" won the 2020 National Excellent Science Works Award from the Ministry of Science and Technology
Time of Update: 2021-12-24
In addition, this general undergraduate book won the 2021 Henan Province Excellent Popular Science Works (Books), and also won the "Most Popular Award" in the 2020 Healthy China ● Cancer Prevention Action Health Popular Science Competition .
-
Clin Cancer Res: PARP inhibitor Veliparib combined with optimized FOLFIRI as a second-line treatment for metastatic pancreatic cancer
Time of Update: 2021-12-24
The study is a randomized phase II trial designed to evaluate the efficacy and safety of mFOLFIRI combined with Veliparib vs FOLFIRI (control: irinotecan, fluorouracil, leucovorin) as a second-line treatment for metastatic pancreatic cancer .
